GILD News and Press, Gilead Sciences Inc. From 04/25/24

2024-04-25 16:19:35 ET More on Gilead Sciences Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? Gilead Sciences: Some Signs Of An Impending Bottom Gilead Sciences Finally Starts Succeeding Gilead Sciences Q1 Preview: HIV pipeline, FY24 gu...

2024-04-25 16:04:59 ET More on Gilead Sciences Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? Gilead Sciences: Some Signs Of An Impending Bottom Gilead Sciences Finally Starts Succeeding Gilead Sciences Q1 Preview: HIV pipeline, FY24 gu...

Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 10% Year-Over-Year to $2.9 billion Oncology Sales Increased 18% Year-Over-Year to $789 million Closed CymaBay Acquisition Resulting in $3.9 billion Acquired IPR&D Charg...

2024-04-25 08:10:00 ET Summary Global stock indices continued an upward trend in March, with both U.S. and non-U.S. stocks rising by 3%. Nvidia unveils groundbreaking Blackwell chip at GTC 2024, CEO predicts AI's influence will expand across all facets of life. Portfolio chang...

2024-04-25 08:00:00 ET Summary Polaris Capital Management, LLC is a leading global value equity manager, serving the investment needs of institutions and individuals since 1995. Polaris has one of the longest global and international equity track records of any firm presently in opera...

Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...

2024-04-24 18:28:32 ET Summary The Inflation Reduction Act has reduced the exclusivity period for small-molecule drugs, potentially leading to earlier market entry for generic drugs. The shortened exclusivity period may create a bullish catalyst for certain stocks in the generic p...

2024-04-24 14:06:00 ET Gilead Sciences ( NASDAQ: GILD ) is scheduled to announce Q1 earnings results on Thursday, April 25th, after market close.... Read the full article on Seeking Alpha For further details see: Gilead Sciences Q1 Preview: HIV pipeline, FY24 guidanc...

2024-04-24 13:02:30 ET Summary Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035, making it a significant opportunity for Madrigal Phar...

2024-04-23 13:12:48 ET Summary The recent lack of M&A activity and rising interest rates have helped trigger an approximate 20% decline in small-cap biotech equities. Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A vol...